Onconetix Inc., a biotechnology company specializing in men's health and oncology, has announced a 1-for-85 reverse stock split effective June 13, 2025. This move, approved at the company's recent special stockholder meeting, will reduce the number of outstanding shares from approximately 44.4 million to 521,863. The company aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Onconetix will continue trading under the symbol "ONCO" with a new CUSIP number.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467098-en) on June 11, 2025, and is solely responsible for the information contained therein.